Lobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells

ArticleAçık Erişim

Özet

Lichen secondary metabolites with many remarkable biological activities are used in cancer treatments due to their low side effects and high anticancer potential. In particular, these metabolites constitute an interesting research area in cancer treatments due to their potential to induce apoptosis and suppress metastasis by inhibiting cancer-related signaling pathways. The Wnt/β-catenin signaling pathway plays a role in important biological processes such as oncogenesis, cell cycle regulation, cell proliferation, metastasis, differentiation, apoptosis, and drug resistance. Therefore, inhibition of this pathway is a potential target in cancer therapies. There is no detailed study explaining the potential anticancer molecular mechanism of the lichen secondary metabolite lobaric acid (LA) on breast cancer. Here, it is aimed to investigate the effect of LA on viability, apoptosis, and migration in MCF-7 cells and to elucidate the relationship between the potential anticancer effect and the Wnt/β-catenin signaling pathway. The dose- and time-dependent viability of LA-treated MCF-7 cells was evaluated by XTT assay, and the IC50 value was determined as 44.21 μg/mL at 48 h. LA increased the apoptotic cell population, as shown by flow cytometry analysis, qPCR, and Western blot results. LA inhibited β-catenin by inducing GSK3-β protein expression, thereby suppressing Wnt/β-catenin target genes. LA might be a natural active compound candidate for breast cancer treatment. © 2025 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.

Anahtar Kelimeler

RDL Kalıcı Bağlantı (PID)
https://rdlopen.rawdatalibrary.net/r/ebyu/10792Resmi atıflarda kullanılan kalıcı adres
DOI
https://doi.org/10.1002/prp2.70142Yayıncı resmi DOI adresi
Tam Kayıt
AlanDeğerDil
dc.contributor.authorKalın, Şeyda Nur
dc.contributor.authorBayındırlı, Kübra Nur
dc.contributor.authorToraman, Emine
dc.contributor.authorGünaydın, Şükran
dc.contributor.authorKeleş, Fatmanur
dc.contributor.authorAltay, Ahmet
dc.contributor.authorBudak, Harun
dc.date.accessioned2026-10-18T20:25:55.792471909Z
dc.date.available2026-10-18T20:25:55.792471909Z
dc.date.issued2025
dc.description.abstractLichen secondary metabolites with many remarkable biological activities are used in cancer treatments due to their low side effects and high anticancer potential. In particular, these metabolites constitute an interesting research area in cancer treatments due to their potential to induce apoptosis and suppress metastasis by inhibiting cancer-related signaling pathways. The Wnt/β-catenin signaling pathway plays a role in important biological processes such as oncogenesis, cell cycle regulation, cell proliferation, metastasis, differentiation, apoptosis, and drug resistance. Therefore, inhibition of this pathway is a potential target in cancer therapies. There is no detailed study explaining the potential anticancer molecular mechanism of the lichen secondary metabolite lobaric acid (LA) on breast cancer. Here, it is aimed to investigate the effect of LA on viability, apoptosis, and migration in MCF-7 cells and to elucidate the relationship between the potential anticancer effect and the Wnt/β-catenin signaling pathway. The dose- and time-dependent viability of LA-treated MCF-7 cells was evaluated by XTT assay, and the IC50 value was determined as 44.21 μg/mL at 48 h. LA increased the apoptotic cell population, as shown by flow cytometry analysis, qPCR, and Western blot results. LA inhibited β-catenin by inducing GSK3-β protein expression, thereby suppressing Wnt/β-catenin target genes. LA might be a natural active compound candidate for breast cancer treatment. © 2025 The Author(s). Pharmacology Research & Perspectives published by British Pharmacological Society and American Society for Pharmacology and Experimental Therapeutics and John Wiley & Sons Ltd.
dc.description.sponsorshipFunding: Open access funding provided by the Scientific and Technological Research Council of T\u00FCrkiye (T\u00DCB\u0130TAK). The authors received no specific funding for this work. The authors have nothing to report.
dc.identifier.doi10.1002/prp2.70142
dc.identifier.issn2052-1707
dc.identifier.issue4
dc.identifier.pmcidPMC12203569
dc.identifier.pmid40576246
dc.identifier.scopus2-s2.0-105009325190
dc.identifier.startpagee70142
dc.identifier.urihttps://rdlopen.rawdatalibrary.net/r/ebyu/10792
dc.identifier.volume13
dc.identifier.wosWOS:001518159000001
dc.language.isoen
dc.publisherJohn Wiley and Sons Inc
dc.relation.ispartofPharmacology Research and Perspectives
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectapoptosis
dc.subjectbreast cancer
dc.subjectcytotoxicity
dc.subjectexpression
dc.subjectWnt/β-catenin pathway
dc.subjectAntineoplastic Agents
dc.subjectbeta Catenin
dc.subjectBreast Neoplasms
dc.subjectCell Movement
dc.subjectCell Proliferation
dc.subjectCell Survival
dc.subjectFemale
dc.subjectGlycogen Synthase Kinase 3 beta
dc.subjectHumans
dc.subjectLichens
dc.subjectMCF-7 Cells
dc.subjectWnt Signaling Pathway
dc.subjectacid
dc.subjectglycogen synthase kinase 3beta
dc.subjectLobaric Acid
dc.subjectprotein Bax
dc.subjectprotein bcl 2
dc.subjectprotein p53
dc.subjectunclassified drug
dc.subjectantineoplastic agent
dc.subjectantineoplastic activity
dc.subjectArticle
dc.subjectcancer growth
dc.subjectcarcinogenesis
dc.subjectcell cycle
dc.titleLobaric Acid Exhibits Anticancer Potential by Modulating the Wnt/β-Catenin Signaling Pathway in MCF-7 Cells
dc.typeArticle
dspace.entity.typePublication
rdl.citation.scopus3
rdl.citation.wos3
rdl.departmentDepartment of Chemistry, Faculty of Science and Arts, Erzincan Binali Yıldırım University, Erzincan, Turkey.
rdl.oa.statusgold
rdl.source.indexSCOPUS
rdl.source.indexWOS
rdl.source.indexPUBMED
rdl.wos.indexScience Citation Index Expanded (SCI-EXPANDED)